Novo Nordisk A/S Common Stock (NVO)

The pharmaceutical company's most promising drug candidate has some potential advantages over its rivals.

Eli Lilly and Company just secured a big win as it looks to expand GLP-1 access, mending its partnership with top pharmacy benefit manager CVS Health.

An upcoming trial result could change how investors think about the weight-loss drug market.

Lexicon (LXRX) Q1 2026 Earnings Transcript

Lilly shares soared more than 18% in May.

These 5 long-term growth stocks could benefit from AI, cybersecurity, GLP-1 drugs, and fintech trends over the next decade

Eli Lilly is working on a new GLP-1 drug, and early results suggest it could be a big winner.

Most of the market's best-known growth names are overbought at this time. That's not the case for several off-the-radar alternatives.

Lilly has split its stock in the past.

Novo Nordisk lost its lead in the GLP-1 race, but Eli Lilly's valuation is a bit rich.

Hims & Hers is acquiring Australian telehealth platform Eucalyptus as part of its international expansion plan while using $350 million in convertible senior notes.

There is no reason to panic just yet.

Eli Lilly's fundamentals matter more than Trump's stock purchases.

These players are seeing exciting results in clinical trials.

It may be too late for Viking to take on the "dark horse" role in the GLP-1 wars.

The efficacy of Eli Lilly's new, still-in-development GLP-1 drug is gaining attention, but don't forget its older GLP-1 drugs just yet.

The pharma giant is taking steps to expand its portfolio.

Hims & Hers plunged 23% after a major Q1 earnings miss, but long-term growth stays intact via its Novo Nordisk GLP-1 partnership and a late 2026 expansion.

Demand for weight loss drugs may fuel growth for more than one player.

If you are looking for a GLP-1 investment, you can buy the leader, the underdog, or the upstart.

Eli Lilly just got more good news, posting promising results for its oral GLP-1 as the firm looks to unlock new sources of demand.

This dark horse in the weight loss drug race is worth keeping on your watch list.

The company is riding an incredible tailwind.

These stocks could look like steals in a few years.

Promising clinical trial data suggests big opportunity with Eli Lilly's retatrutide GLP-1 candidate.